Evidence map›Paper›PMID 42608632›Full record

ArticleOncology and therapy2026

Exceptional Cure of a Patient with Progressive Advanced Squamous-Cell Lung Cancer after Selenite Treatment followed by Chemotherapy: A Case Report.

Ola Brodin, Carlos Fernandez Moro, Mattias Hedman, Ozan Aricak, Tímea Szekerczés, Per Grybäck, Mikael Björnstedt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ola BrodinDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge, Sweden. ola.brodin@regionstockholm.se.
Carlos Fernandez MoroDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge, Sweden.
Mattias HedmanTema Cancer, Karolinska University Hospital, Solna, Sweden.
Ozan AricakDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge, Sweden.
Tímea SzekerczésDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge, Sweden.
Per GrybäckDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Huddinge, Sweden.
Mikael BjörnstedtDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge, Sweden. mikael.bjornstedt@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous (i.v.) sodium selenite has been evaluated in patients with advanced cancer, but its potential clinical and biomarker-related effects remain incompletely understood. We report a patient with advanced squamous-cell lung cancer who was treated with high-dose intravenous sodium selenite within the SECAR phase I trial. The patient had recurrent, progressive disease after previous chemotherapy, radiotherapy, and targeted treatment, and no further standard treatment options were available. Sodium selenite was administered according to the study protocol and was followed by gemcitabine plus carboplatin. Imaging shortly after treatment showed stable disease; however, the patient subsequently improved clinically followed by gradual tumor regression. 2-[

Indexed as

Case reportComplete responseImmunomodulationSodium seleniteSoluble PD-L1Squamous-cell carcinoma of the lung

Identifiers

PMID42608632
PMCPMC13574738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.